About ARCH Venture Partners
ARCH invests primarily in companies co-founded with leading scientists and entrepreneurs, concentrating on bringing to market innovations in life sciences, physical sciences, and information technology. ARCH enjoys special recognition as a leader in the successful commercialization of technologies developed at academic research institutions and national laboratories. ARCH currently manages seven funds totaling nearly $1.5 billion and has invested in the earliest venture capital rounds for more than 120 companies. ARCH investors include major corporations, pension funds, endowment funds, financial institutions, and private investors. The partnership is led by six managing directors and a team of venture partners, principals, associates, and technology specialists. For more information, please visit ARCH's website at www.archventure.com
|
About Flagship Ventures
Realizing Entrepreneurial Innovation is the mission of Flagship Ventures. The firm operates through two synergistic units: VentureLabs which invents and launches transformative companies, and Venture Capital, which finances and realizes innovative, early-stage companies. Founded in 2000, and based in Cambridge, Massachusetts, Flagship Ventures manages over $900 million in capital. The Flagship team innovates and invests in three principal business sectors: therapeutics; medical technologies; and sustainability/clean technology. Whether we are founding or funding new ventures, our commitment to maximizing the value of entrepreneurial innovation is unparalleled.
www.flagshipventures.com
|
About Lilly Ventures
Lilly Ventures is the venture capital arm of Eli Lilly and Company responsible for life science investing in North America and Europe. Our primary goal is to facilitate the success of companies in our areas of focus through early to expansion stage investments and value-adding resources. Lilly Ventures currently has $200 million under management and focuses on three major areas of interest.
Biotechnology: targeting investments in biotechnology companies that leverage proprietary drug discovery or development technologies to build a multi-product pipeline.
Medical Technology: targeting investments in companies focusing on the convergence of pharmaceuticals, devices or diagnostics.
Healthcare IT: targeting investments in expansion stage companies with innovative network technologies that promise to have a transformational impact on the current pharmaceutical business model.
Our investment approach centers on working with superior management teams to help them realize the financial potential of their ideas. Accordingly, we provide both financial and intellectual resources to accelerate the management teams' path to success.
For more information, please visit Lilly Ventures' website at www.lillyventures.com
|
About Venrock
Venrock is a premier venture capital firm with offices in Palo Alto, CA; New York, NY; and Cambridge, MA. Originally established as the venture capital arm of the Rockefeller family, Venrock continues an eight-decade tradition of partnering with entrepreneurs to establish successful, enduring companies. Having invested $2.6 billion in over 450 companies resulting in 128 IPOs and 137 M&As over the past 42 years, Venrock's investment returns place it among the top tier venture capital firms that have achieved consistently superior performance. With a primary focus on technology, healthcare, and energy, portfolio companies have included Adify, Adnexus Therapeutics, Apple Computer, Athenahealth, Centocor, Check Point Software, DoubleClick, Gilead Sciences, Idec Pharmaceuticals, Illumina, Intel, Millennium Pharmaceuticals, Sirna Therapeutics, StrataCom, and Vontu. For more information, please visit Venrock's website at www.venrock.com and follow the firm on Twitter @venrock.
|
